Osteoarthritis Injection Availability in Hospital Pharmacies

This covers why osteoarthritis injections are stocked so differently across hospitals, what the device-versus-drug distinction actually means for procurement, what the evidence says about each option, and what a hospital pharmacy should do about it.

Why is hyaluronic acid stocked so differently from a typical drug?

Under India's Medical Device Rules 2017, devices are classified by risk into four categories. Intra-articular hyaluronic acid products fall under medical device rather than pharmaceutical regulation in most jurisdictions that separate the two, which changes how a hospital procures and reorders it. A pharmacy team used to ordering scheduled drugs through a standard wholesale-drug-licence channel sometimes runs a completely separate procurement process for a device-classified product like this.

That regulatory split matters operationally. Device-classified products don't carry the same national price ceiling or essential-medicines-list status that would otherwise guarantee baseline supply chain priority. A hospital's hyaluronic acid stock depends far more on its own direct supplier relationship than on any government-mandated minimum availability. A smaller nursing home without a standing device-supplier contract feels this gap acutely the first time a specialist books a course of injections on short notice.

Why can't PRP be "stocked" the way other injections are?

Platelet-rich plasma has no manufactured drug to hold in inventory, since it is prepared at the point of care by drawing and processing the patient's own blood. What a hospital actually needs on hand is the processing kit, centrifuge capacity and trained staff time, not a shelf-stable injectable product.

This means PRP availability is really a service-capacity question rather than a stocking question in the conventional pharmacy sense. A hospital can run out of PRP kits the same way it runs out of any consumable, but it can never be "out of stock" of PRP itself the way it can be out of stock of a manufactured drug. Conflating the two leads pharmacy teams to plan for the wrong constraint, ordering more kits when the real bottleneck is centrifuge time or a trained phlebotomist's schedule.

Does the evidence support prioritising one injection type in a hospital's stocking plan?

A systematic review of injection-based knee osteoarthritis management guidelines found real disagreement between clinical societies on hyaluronic acid, with some endorsing it for mild-to-moderate disease and others declining to recommend it given inconsistent trial evidence. A comprehensive narrative review of PRP evidence similarly found leukocyte-poor PRP outperforming hyaluronic acid in some trials while other high-quality placebo-controlled studies showed no lasting benefit past six to twelve months.

Given that split evidence base, a hospital pharmacy shouldn't treat either category as the clearly superior default to stock in bulk over the other. The more defensible approach stocks both at a level matched to the specific orthopaedic department's actual case mix and the treating specialists' own protocol preferences. That beats betting the formulary on one category based on manufacturer marketing rather than settled consensus evidence, since the consensus genuinely isn't settled yet.

What did India's own expert consensus find about availability and practice variation?

The 2019 Indian expert consensus report on hyaluronic acid use, developed from discussion among 78 orthopaedic surgeons at national and regional meetings, was created specifically because no standard national guideline existed, and that vacuum had produced wide variation in how and when hyaluronic acid gets used across Indian practice. That variation in prescribing directly produces variation in what hospitals find worth stocking.

A hospital in a region where local specialists prescribe hyaluronic acid routinely for mild-to-moderate disease develops very different reorder patterns than one where specialists reserve it for a narrower set of patients. Absent a national standard, a hospital's own department-level prescribing data is the only reliable input for its stocking plan.

What should a hospital pharmacy actually do about this stocking gap?

Track hyaluronic acid and PRP kit usage against the specific orthopaedic department's own booking calendar rather than a generic essential-medicines reorder point, since neither category benefits from the safety net a national essential list would otherwise provide. Build forward stocking around scheduled procedure lists, since both categories carry real shelf-life and cold-chain considerations that make speculative overstocking expensive.

Our managed hospital pharmacy services guide covers how a hospital keeps device-classified and specialty injectable stock like this reliably available in-house so a scheduled patient isn't sent to an outside supplier mid-course, and our prescription leakage piece covers what that referral-out costs a hospital in lost revenue and lost follow-up visibility.

Sources

1. 1Viscosupplementation for Management of Knee Osteoarthritis from an Indian Perspective: An Expert Consensus Report — National Institutes of Health, National Library of Medicine, Pain and Therapy, 2019
2. 2Injection-Based Management of Osteoarthritis of the Knee: A Systematic Review of Guidelines — National Institutes of Health, National Library of Medicine
3. 3Platelet-Rich Plasma for Knee Osteoarthritis: A Comprehensive Narrative Review — National Institutes of Health, National Library of Medicine, 2025
4. 4Classification of Medical Devices — Central Drugs Standard Control Organisation, Medical Device Rules 2017
5. 5National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation

This article is for informational purposes and is not a substitute for professional medical advice. Injection choice for osteoarthritis is a clinical decision made between a patient and their treating orthopaedic specialist; this article does not recommend a specific treatment for any individual case.